Wilmington, N.C., January 15, 2008 -- AAIPharma’s sterile manufacturing plant in Charleston, SC USA received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilized products. The MHRA approval certifies the plant to produce these products for shipment to countries in the European Union (EU) and comes on the heels of a $1,500,000 renovation of the plant. Along with prior approvals from the US Food and Drug Administration (FDA), this approval positions the plant to deliver aseptic contract manufacturing services to clients wishing to supply both commercial and clinical sterile drug products throughout the US and Europe.
